Abstract 337P
Background
T and NK-cell lymphoma represents approximately 10 to 15% of all non-Hodgkin’s lymphoma worldwide. However, the epidemiology of underlying subtypes varies geographically. As such, we aim to investigate disease patterns, patient demographics and survival outcomes in a multiethnic cohort from Singapore.
Methods
We performed a retrospective analysis on various histological subtypes of T and NK-cell lymphoma diagnosed from 2004 to 2022 (n=325) at the National Cancer Centre Singapore. Clinico-demographic data were collated across major ethnic groups (Chinese, Malay and Indian) and pre-defined age groups (<40, 40-65, and >65 years). Overall survival was estimated using the Kaplan-Meier method.
Results
In our study cohort, the median age was 55 years (range, 15-88), with a male predominance (61.2%). Major ethnic groups include Chinese (72.0%), followed by Malays (10.5%) and Indians (4.6%). In terms of age at diagnosis, the majority presented between ages 40 to 65 years (50.8%) in comparison to other age groups (<40 years, 24.0%) and (>65 years, 25.2%). The most common histological subtypes include angioimmunoblastic T-cell lymphoma/peripheral T-cell lymphoma T-follicular helper phenotype (AITL/PTCL-TFH) (38.8%), natural killer/T-cell lymphoma (NKTCL) (17.2%), and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) (12.6%). In analysis by age groups, AITL/PTCL-TFH was the dominant diagnosis. The next most common diagnosis was NKTCL for patients above 65 years, and was PTCL-NOS in patients under 40 years. Further analysis of ethnic distribution amongst these common subtypes revealed a similar trend, though interestingly, NKTCL was not observed amongst the Indian subgroup. In the whole cohort, the median overall survival was 21.4 years with a 5-year OS of 75.6%. 5-year OS was significantly worse for PTCL-NOS as compared to AITL/PTCL-TFH or NKTCL (62.5% vs 79.2% and 78.5%, respectively; log-rank p=0.0225). Age at diagnosis, disease stage and IPI risk groups were significantly prognostic, but not ethnic groups and sex.
Conclusions
Through this analysis we identified unique demographic and survival patterns in T and NK-cell lymphoma within our local population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Tanoto Foundation Professorship in Medical Oncology New Century Foundation Limited Ling Foundation Singapore Ministry of Health’s National Medical Research Council Research Transition Award (TA21jun-0005) and Large Collaborative Grant (OFLCG18May-0028).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract